China Levofloxacin Market, 2010-2019 - New Study Released

In recent years, the market size of antibiotics has exceeded USD 30 billion around the world with the average growth rate being about 8%. In the drug market in China, anti-infectious drug has been the best-selling drug for many years, accounting for 30% of the total sales value.
Quinolones, an up-rising antimicrobial, has increasingly attained attention around the world. As a levo isomer of ofloxacin, levofloxacin has the same spectrum as ofloxacin with stronger antibacterial activity and lower toxicity. First developed and marketed by Daiichi Sankyo Co., Ltd n Japan in 1994, levofloxacin, raw materials and tablets included, has already turned generic in China now.
The sales of levofloxacin has been impressive in China too. In 1998, a year after marketing, levofloxacin ranked 98 in the TOP100 best-selling drugs, keeping moving up year by year. According to CRI's market survey, its sales value rose from CNY 660 million in 2010 to CNY 855 million in 2014 with CAGR during this period reaching 6.69%. Daiichi Sankyo Co., Ltd (Beijing), Yangtze River Pharmaceutical Group, China Resources Double Crane Pharmaceutical Co., Ltd, Santen Pharmaceutical Co., Ltd (Japan) and Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory have occupied the majority of the market share, among which Daiichi Sankyo Co., Ltd (Beijing) has the largest market share of 31% for sales value in 2014. In 2014, levofloxacin injection occupied about 70% of the market for sales value while tablets and eye drops shared the rest.
Levofloxacin market is expected to keep growing in the next few years in China.

Full Report Details at
- http://www.fastmr.com/prod/1015927_china_levofloxacin_20102019.aspx?afid=301

Readers can get at least the following information from this report:

* market size of levofloxacin in China
* competitive landscape of levofloxacin in Chinese market
* price of levofloxacin made by different enterprises in China
* market outlook of levofloxacin in China

The author suggests the following groups of people purchase this report:

* manufacturers of antibiotics
* investors/ research institutions interested in Chinese medicine market
* any interest in the Chinese medicine market, please contact CRI for customized survey service

Companies Mentioned in this Report: Yangtze River Pharmaceutical Group, China Resources Double Crane Pharmaceutical Co., Ltd, Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory, Santen Pharmaceutical Co., Ltd (Japan), Daiichi Sankyo Co., Ltd

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Hiran Orgochem Ltd. (506170) - Financial and Strategic SWOT Analysis Review
- China Resources Double-Crane Pharmaceutical Co., Ltd. (600062) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Neuland Laboratories Limited (NEULANDLAB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Zhejiang Jingxin Pharmaceutical Co., Ltd (002020) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Zhejiang Medicine Co., Ltd. (600216) - Pharmaceuticals & Healthcare - Deals and Alliances Profile